Health
Osimertinib offers a hint of added benefit for NSCLC patients who have received adjuvant chemotherapy – News-Medical.net
Osimertinib was the first drug to be approved for adjuvant treatment after complete tumour resection in adults with stage IB…
Osimertinib was the first drug to be approved for adjuvant treatment after complete tumour resection in adults with stage IB to IIIA non-small cell lung cancer (NSCLC). In an early benefit assessment, the German Institute for Quality and Efficiency in Health…
Continue Reading
-
General5 hours agoAustralian celebrity chef Peter Russell-Clarke dies aged 89
-
Noosa News22 hours agoBrisbane’s original 1979 electric trains take one last journey
-
General21 hours agoParis opens River Seine for public swimming for first time since 1923
-
General19 hours agoDr Daniel Hunt, Michael Long and Christine Anu celebrated at 50th NAIDOC Week Awards